Heron Therapeutics (HRTX)
Sells U.S. hospital injectables for postsurgical pain and nausea prevention.
Something off on this page? Send us feedback.
Commercializes four U.S.-approved products across one segment: ZYNRELEF for postsurgical pain, APONVIE for postoperative nausea and vomiting, and CINVANTI and SUSTOL for chemotherapy-induced nausea and vomiting. Sales run through specialty distributors and wholesalers, with SUSTOL being wound down while updates are evaluated.
Commercializes a focused U.S. portfolio of hospital and specialty injectables. ZYNRELEF is used for postsurgical pain, APONVIE for postoperative nausea and vomiting, and CINVANTI and SUSTOL for chemotherapy-induced nausea and vomiting.
Operates as one reportable segment with revenue generated from U.S. customers. Products move through specialty distributors and full-line wholesalers to healthcare providers and hospitals, supported by a compact commercial team and a Crosslink Network co-promotion agreement for ZYNRELEF orthopedic use.
Execution depends on hospital access, payer reimbursement, FDA-approved labeling, outsourced manufacturing, and competition from branded and generic antiemetics and analgesics. ZYNRELEF reimbursement is tied to separate Medicare support under the NOPAIN Act, while SUSTOL commercialization is being wound down as product updates are evaluated.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 11, 2026 | H.C. Wainwright | Downgrade | ||
| Aug 11, 2026 | HC Wainwright & Co. | Downgrade | ||
| Jun 3, 2026 | Needham | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $42.7M · Total debt $148.4M · Total assets $252.3M · Shareholders' equity $6.9M
- Revenue
- $37.7M
- Operating income
- −$2.0M
- Net income
- −$5.5M
No dividends on record.
| Institutions | 70.97% | 134.74M shares | |
|---|---|---|---|
| 170 holders · as of Jun 30, 2026 | |||
| Insiders | 1.07% | 2.03M shares | |
| 11 holders · as of Aug 10, 2026 | |||
| Other | 27.96% | 53.08M shares | |
| remainder | |||
189.85M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Rubric Capital Management LPInstitution | 15.83% | 30.05M | as of Jun 30, 2026 |
Clearline Capital LPInstitution | 6.00% | 11.38M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 5.56% | 10.55M | as of Jun 30, 2026 |
Velan Capital Investment Management LPInstitution | 4.61% | 8.75M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.10% | 7.78M | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Amneal Pharmaceuticals
Ready-to-use NK1 injectable alternative for CINV prevention
- Pacira BioSciences
EXPAREL leads non-opioid postsurgical local analgesia
- Merck
EMEND anchors branded NK1 competition in CINV
- Pfizer
Local-anesthetic and ondansetron injectables overlap in hospitals
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Heron Therapeutics | $0.2891 | −3.31% | $56.6M | — | — | 0.4 | +1.3% |
| Amneal Pharmaceuticals | $19.38 | −0.64% | $6.23B | 40.0 | 19.4 | 2.0 | +9.9% |
| Pacira BioSciences | $24.77 | +0.30% | $971.6M | 70.3 | 8.0 | 1.3 | +6.2% |
| Merck | $149.84 | −0.71% | $372.73B | 120.7 | 17.4 | 5.6 | +5.1% |
| Pfizer | $28.03 | +0.36% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Median | 55.2 | 13.7 | 2.2 | +5.7% |